logo
Convenience stores eyed as way to provide morning-after pill

Convenience stores eyed as way to provide morning-after pill

UPI6 days ago

St. PAUL, Minn., May 27 (UPI) -- Women's health advocates say they want to expand the availability of morning-after pills to convenience stores as new state abortion laws sow confusion about their legality and pharmacies are closing nationwide.
Emergency contraception deserts are arising in many areas of the United States where morning-after pills, although still legal everywhere, have become almost impossible to find due to a combination of misconceptions about their function and the ongoing drug store closures, healthcare experts told UPI.
Some suggest that wider availability of morning-after pills for women at convenience stores and other non-traditional outlets, such as gas stations, grocery stores, corner delis, travel retailers and hotels, could ease the problem.
Levonorgestrel, also known as "Plan B," or the morning-after pill, is a first-line oral emergency contraceptive pill approved from the U.S. Food and Drug Administration and the World Health Organization to prevent pregnancy. It is to be used within 72 hours of unprotected sexual intercourse or when a presumed contraceptive failure has occurred.
It has an average cost about $40 to $50, with generics generally costing less at about $11 to $45.
Approved in 2007
Levonorgestrel earned FDA approval to be sold over the counter without a prescription in 2007 after the agency deemed it to be safe following years of debate. Since then, it has been available without a prescription at drug stores alongside male contraceptives, such as condoms.
But while condoms are widely available in many different settings, women's health advocates are warning that the lack of similar availability for Plan B pills outside traditional pharmacies has created emergency contraception deserts in many areas.
Adding to the problem is confusion about how Plan B pills function and whether they're still legal in the wake of the Supreme Court's landmark 2022 Dobbs vs. Jackson Women's Health Organization decision that allowed states to enact local abortion bans.
Uncertainty has arisen in states with the toughest abortion restrictions about whether the pills even remain legal as people confuse levonorgestrel, which prevents pregnancy, with mifepristone and misoprostol, which induce medical abortions, according to the women's health advocates.
Polls indicate that as many as 73% of people incorrectly think morning-after pills can end a pregnancy in its early stages. In fact, the right to such contraception is currently protected by two other landmark Supreme Court decisions, Griswold vs. Connecticut (1965) and Eisenstadt vs. Baird (1972), but this confusion is believed to have led to declines in their use since Dobbs, they argue.
Challenging economics
They also point to the challenging economics of the retail pharmacy industry. Walgreens, for instance, announced in October that it will close roughly 1,200 of its stores through 2027 and seeks to close at least 500 stores by the end of 2025 alone. It says one-quarter of its roughly 8,700 U.S. store locations are unprofitable.
About one-third of all U.S. pharmacies have closed since 2010 due to mergers of large pharmacy chains and the closure of stores deemed not profitable enough, according to a study published last year.
As these factors accelerate, some 7,000 U.S. ZIP codes in both urban and rural areas now qualify as emergency contraception deserts in which "healthcare services are lacking and there are few or no drug stores to fulfill the needs of the approximately 23 million women of childbearing age who live there," according to Cadence OTC, an Oakland, Calif.-based public benefit company that makes and markets a brand of levonorgestrel called "Morning After Pill."
Cadence officials say they have spent the last few years working hard to convince convenience retailers that stocking Morning After Pill benefits both their bottom lines and the health of their communities.
They have so far succeeded in getting the product into 11,000 locations in 48 states after forging a partnership with Lil' Drug Store Products, the nation's top supplier of health and beauty care products to convenience stores.
Sales in remote areas
"A lot of college campuses and military bases are in remote areas and are filled with young people, so these are priorities for contraceptive access," the company said in a statement issued to UPI. "C-stores are in every neighborhood and they are open long hours."
Stocking emergency contraceptives makes sense for convenience stores as a way to replace revenue lost as cigarette purchases decline, Cadence said, adding, "Urgent healthcare products are a logical expansion space for C-stores, and the profit margins are generally higher than food and soft drinks.
"Ninety percent of C-stores already carry condoms, so it makes sense to offer female contraceptives. as well."
The challenge "is to increase awareness among consumers to think of C-stores for these healthcare items," company officials said in a statement. "Many C-stores are excited about playing a more important role in serving young women, leaning into urgent OTC healthcare is a smart business strategy."
Health benefit
One gynecologist who has studied the availability of emergency contraception in the aftermath of the Dobbs decision said the push to get morning-after pills into convenience stores would provide a public health benefit.
Dr. Frank "Will" Williams III, who specializes in treating complicated pregnancies for Ochsner Health in New Orleans, co-authored a 2023 study that found only 35% of locally owned, independent pharmacies in the city had emergency contraception in stock. They were also much more likely than chain stores to keep the product behind the counter, require identification and carry no brand that cost under $50.
"The independent pharmacies are the ones who are not likely to have a gaggle of lawyers on retainer who can tell them, 'Yes, emergency contraception is fine, they're not discussed at all in any of the abortion legislation, you guys can keep going with this,'" Williams told UPI.
"They didn't have that luxury, so when Dobbs came through, that's where we really saw an absence of access to contraception."
Now with many chain-owned pharmacies closing as well, the push to expand emergency contraception into non-traditional retail venues is needed, he said.
Greater accessibility
"If I'm traveling and need ibuprofen, I can find it a grocery store or convenience store, so there's no reason why that can't also be true for emergency contraception," Williams said. "Whatever we can do to make sure that people have accessible options regarding their health seems like a win to me."
Agreeing is Dima Mazen Qato, an associate professor at the University of Southern California's Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences and a senior scholar at the USC Schaeffer Center for Health Policy & Economics.
Qato has researched the causes behind the wave of pharmacy closures and their effects on socioeconomic and racial health disparities across the country.
Getting emergency contraception into non-traditional venues "makes sense, although I don't know what the price point is for it to be affordable and to actually be used by those who need it," she told UPI.
"It's important to make sure it's affordable at these different access points, and also that there's no ID required -- that's just available like anything else."
She added it's "definitely a great way to distribute emergency contraception, especially in states that, since Dobbs, have banned or partially banned abortion care. I think any effort to expand access to emergency contraception is needed across the country."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Two people rescued from small plane crash in Long Island Sound
Two people rescued from small plane crash in Long Island Sound

Yahoo

time3 hours ago

  • Yahoo

Two people rescued from small plane crash in Long Island Sound

June 1 (UPI) -- Crews rescued two people aboard a small plane that crashed into Long Island Sound Sunday near a Connecticut airport, according to the FAA and U.S. Coast Guard. The Piper PA-32 plane went down about 10:30 a.m. south of the Tweed New Haven Airport in New Haven, a statement from the FAA said. "The two persons onboard the aircraft were rescued and in stable condition," the Coast Guard said in a statement, according to ABC News. The Coast Guard dispatched a 45-foot New Haven-based rescue boat to the scene after the Sector Long Island Sound Command Center received notification of the incident from the air traffic control tower that the plane had gone down near the Thimble Islands close to Branford, Ct. The rescued passengers were taken to the Stony Creek Pier in Branford, the Coast Guard said. The FAA is investigating the incident.

Opinion - No, OBGYNs are not systematically fleeing states that banned abortion
Opinion - No, OBGYNs are not systematically fleeing states that banned abortion

Yahoo

time7 hours ago

  • Yahoo

Opinion - No, OBGYNs are not systematically fleeing states that banned abortion

The Supreme Court's 2022 Dobbs decision ended decades of national judicial precedent protecting legal abortion. As of today, 12 states enforce bans on nearly all abortions, and seven states are enforcing bans on abortions after six, 12 or 18 weeks' gestation. Also, numerous lawsuits have been filed attempting to restrict abortion access in states where it is still legal. Although obstetricians and gynecologists have always had to operate under the risk of malpractice lawsuits, state-level abortion bans added a new layer of legal risk to delivering established standards of care. In this climate, surveys have revealed evidence of obstetrician-gynecologist in states that have banned abortion feeling constrained or afraid. Reports and studies have documented a decline in OBGYN residency applications to programs located in those states. And numerous media outlets have run stories suggesting that OBGYNs are leaving states with abortion bans to practice where abortion is still legal. Since obstetrician-gynecologist provide many different kinds of care — including contraceptive, delivery and postpartum care — these stories have raised serious concerns about the availability of all forms of reproductive health care throughout much of the country. But in research just published in JAMA Network Open, we and our co-authors find no evidence of such an exodus of obstetrician-gynecologist physicians from states with abortion bans. Using administrative records managed by the Centers for Medicare and Medicaid Services on all physicians who bill insurance, we looked at the movement of obstetrician-gynecologists between states with different abortion policy environments from just before the Dobbs decision to two years after. Out of all obstetrician-gynecologist who were practicing at the start of 2022 in states with abortion bans, 94.2 percent were still practicing in September 2024. This percentage is statistically indistinguishable from the 94.8 percent of obstetrician-gynecologists who have remained in states where abortion is threatened and the 95.8 percent who have remained in states where it is protected. OBGYNs also continued to move into states with abortion bans at similar rates to other states. From the start of 2018 to the end of 2024, the total number grew by 8.3 percent in states with abortion bans, by 10.5 percent in states where it is threatened and by 7.7 percent in states where it is protected. Trends in the number of practicing obstetrician-gynecologists were also comparable to those in the number of physicians in other specialties in states where abortion is banned. We also considered trends in the practice locations of recent residency graduates and subspecialists in maternal-fetal medicine, as well as trends in the share of OBGYNs who are female and who are licensed to practice in more than one state. All were similar between states, regardless of abortion's legality. Our findings are not unique. In December 2024, an independent group of researchers using a different data set came to the exact same conclusions. And in March, researchers showed that the number of obstetrician-gynecologists in states with bans has increased since Dobbs, though perhaps at a slower rate than in a group of states with mixed status. So why has a narrative that obstetricians are leaving and avoiding states with abortion bans become so prominent? A closer look at the media coverage reveals that different reporters have interviewed the same small handful of 15 or so physicians who left states with bans. Those interviews, coupled with survey evidence on the strain physicians are facing, have led to conclusions that doctors are fleeing states with bans. But it just isn't true. Evidence on trends in residency applications also needs additional context. While states with bans have seen larger declines in obstetrician-gynecologist residency applications than states without bans, nearly all such positions continue to be filled at pre-Dobbs levels. Broader doctor shortage issues that predate the Dobbs decision, including those leading to closures of hospital labor and delivery departments, have been conflated with the effects of the Supreme Court ruling as well. We pursued this research because it is crucial to understand all of the facts to make progress on the availability and quality of reproductive health care. Focusing on a physician exodus that is not actually happening distracts us from addressing the real, plentiful problems with the delivery of medical care. Our findings imply that while removing abortion bans would likely improve the quality of care that obstetricians can provide by giving them the ability to follow established standards of care, it is unlikely to shift the economic and structural forces driving maternal ward closures and doctor shortages. When it comes to the availability of care, those are the forces that deserve policy attention. Our study is by no means the final word. Physicians feeling constrained by abortion bans may be 'sheltering in place' for now, with decisions of where to live and work shaped by other factors. The coming years could well see different trends. But at this point, ensuring high-quality reproductive health care in states affected by abortion bans will require supporting the obstetricians who, at heightened personal risk, continue to provide essential care to the best of their ability. Becky Staiger is an assistant professor in health policy and management in the School of Public Health at the University of California, Berkeley. Valentin Bolotnyy is a Kleinheinz Fellow at Stanford University's Hoover Institution. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

U.S. FDA Accepts New Drug Application Under Priority Review for sevabertinib (BAY 2927088) in HER2-Mutant Non-Small Cell Lung Cancer
U.S. FDA Accepts New Drug Application Under Priority Review for sevabertinib (BAY 2927088) in HER2-Mutant Non-Small Cell Lung Cancer

Yahoo

time8 hours ago

  • Yahoo

U.S. FDA Accepts New Drug Application Under Priority Review for sevabertinib (BAY 2927088) in HER2-Mutant Non-Small Cell Lung Cancer

Regulatory submission is based on positive results from the ongoing Phase I/II SOHO-01 trial in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC). Investigational agent sevabertinib (BAY 2927088) is an oral, small molecule, tyrosine kinase inhibitor (TKI) being evaluated as a potential new targeted therapy for patients with NSCLC harboring HER2 activating mutations. The U.S. Food and Drug Administration (FDA) grants Priority Review designation for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition. WHIPPANY, N.J., May 28, 2025--(BUSINESS WIRE)--Bayer announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's new drug application (NDA) and granted Priority Review designation for the investigational compound sevabertinib (BAY 2927088), an oral, small molecule, tyrosine kinase inhibitor (TKI), for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have activating human epidermal growth factor receptors 2 (HER2) (ERBB2) mutations and who have received a prior systemic therapy. "Patients with HER2-mutant NSCLC are predominantly women, may be of younger age and non-smokers. The FDA's decision to grant Priority Review designation to our application for sevabertinib is a significant milestone that supports our ongoing efforts to develop healthcare solutions that help people living with lung cancer," said Christine Roth, Executive Vice President, Global Product Strategy and Commercialization and Member of the Pharmaceuticals Leadership Team at Bayer. "If approved, sevabertinib will provide an additional treatment option for previously treated patients with advanced NSCLC harboring a HER2-activating mutation." The NDA for sevabertinib is based on positive results from the ongoing Phase I/II SOHO-01 trial. Results from patients with advanced NSCLC harboring a HER2-activating mutation, who experienced disease progression after ≥1 systemic therapies for advanced disease and were naïve to HER2-targeted therapy.1 The FDA grants Priority Review designation for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition.2 In 2024, the FDA granted sevabertinib Breakthrough Therapy designation for the treatment of adult patients with unresectable or metastatic NSCLC whose tumors have activating HER2 (ERBB2) mutations, and who have received a prior systemic therapy. The Breakthrough Therapy designation was supported by preliminary clinical evidence from the SOHO-01 trial. The FDA grants Breakthrough Therapy designation for the evaluation of investigational medicines that are intended to treat a serious condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s).3 About sevabertinib (BAY 2927088)4Sevabertinib is an investigational agent and has not been approved by any health authority for use in any country, for any indication. It is currently being evaluated as a potential new targeted treatment option for patients with NSCLC harboring human epidermal growth factor receptors 2 (HER2) activating mutations. Sevabertinib is also being studied in patients with metastatic or unresectable solid tumors harboring HER2-activating mutations. Sevabertinib is an oral, reversible tyrosine kinase inhibitor (TKI) that potently inhibits mutant HER2, including HER2 exon 20 insertions and HER2 point mutations, as well as epidermal growth factor receptors (EGFR), with high selectivity for mutant vs wild-type EGFR. Investigational agent sevabertinib is derived from Bayer's strategic research alliance with the Broad Institute of MIT and Harvard in Cambridge, MA, USA. About Non-Small Cell Lung Cancer (NSCLC)Lung cancer is the leading cause of cancer-related deaths in the U.S.5 Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for more than 85% of cases.4 Activating HER2 mutations are found in 2% to 4% of advanced NSCLC.6 80% of people diagnosed with NSCLC have already progressed to advanced stages, which makes it more difficult to treat.7 Patients with HER2-mutant NSCLC currently face limited targeted therapies.8 About Oncology at BayerBayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The company has the passion and determination to develop new medicines that help improve and extend the lives of people living with cancer. The oncology franchise at Bayer includes several marketed products across diverse indications and multiple compounds in different stages of clinical development. We have a wealth of expertise in areas including Tumor Cell Intrinsic Pathways, Targeted Radionuclide Therapies, and selective Next-Generation Immuno-Oncology. With our portfolio we are advancing cancer treatments from early to metastatic stage, with the goal of extending survival while limiting side effects for the cancer patients we serve. About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to © 2025 BayerBAYER and the Bayer Cross are registered trademarks of Bayer. Find more information at Our online press service is just a click away: Follow us on Facebook: Follow us on X: Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. References Le X, et al. Safety and efficacy of BAY 2927088 in patients with HER2-mutant NSCLC: expansion cohort from the phase I/II SOHO-01 study. Presented at the 2024 IASLC World Conference on Lung Cancer; San Diego, CA, September 7-10, 2024. PL04.03. U.S. Food and Drug Administration. "Priority Review." Accessed April 21, 2025. U.S. Food and Drug Administration. "Breakthrough Therapy." Accessed April 21, 2025. First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/​or Human Epidermal Growth Factor Receptor 2 (HER2). Clinical trial registration No. NCT05099172. Accessed April 21, 2025. American Cancer Society. Key Statistics for Lung Cancer. Accessed April 21, 2025. Nützinger, J, et al. (2023). Management of HER2 alterations in non-small cell lung cancer - The past, present, and future. Lung cancer (Amsterdam, Netherlands), 186, 107385. Yale Medicine. "Non-Small Cell Lung Cancer." Accessed April 21, 2025. Uy NF,et al. HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies. Cancers (Basel). 2022 Aug 27;14(17):4155. doi: 10.3390/cancers14174155. PMID: 36077691; PMCID: PMC9454740. View source version on Contacts Media Contact: Polina Miklush, Tel +1 862.431.8817Email:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store